Yesterday I wrote about how difficult it is to tell different cell lines apart, including normal stem cells and cancer stem cells, especially since some accumulate accumulate oncogenic mutations that may make them seem more similar. A new paper is coming out that makes this case on a genomic level. Tomorrow’s Cell Stem Cell edition …
Devil in the details: small oncogenic lesions in iPS cells & ESC Read More »
Sheng Ding’s lab reports today in Cell Stem Cell (you can read it here) that they have replaced all genetic factors in a new iPS cell reprogramming method except Oct4. The other factors were replaced by chemical compounds. Thus, we continue a major transition in the iPS cell field away from genes and toward chemicals. …
From genes to chemicals: iPS cell field, reprogramming in transition Read More »
If IPS cells are not ready for prime time, it is probably due to these three critical challenges for these amazing cells. TUMORIGENICITY Those of us who work with IPS cells are very excited about their potential for use in regenerative medicine therapies. One serious hurdle we have talked about in the past is tumorigenicity. …
Not ready for prime time: the three critical challenges for IPS cells Read More »
Update in 2020: Wow, a lot has changed since this post almost 10 years ago, but Cell Stem Cell remains the main publisher of IPS cell articles still. The young iPSC field has published a truly massive number of papers in just 4 years. Searching ISI Web of Knowledge for papers with titles reflecting iPSC …
Striking iPS cell research publishing trends: what do they mean? Read More »
Update in 2020: It seems now after all these years that the consensus in the now more mature field is that IPSCs and ESCs are nearly identical in most cases, and both have some of the same translational challenges such as teratoma-forming activity. It’s interesting to read this post from nearly 10 years ago and …
iPS cells coming into focus: not quite so similar to ESC after all Read More »